NovaBay Pharmaceuticals, Inc reports that the United States Patent and Trademark Office has approved the issuance of US Patent No 7,462,361 to NovaBay for novel Aganocide compounds including its current lead compound, NVC-422 (N,N-dichloro-2,2-dimethyltaurine). The patent will expire on April 24, 2026.
"The issuance of this patent – the first one issued for the Aganocide compounds -significantly strengthens our patent portfolio, and represents a valuable asset for both NovaBay and its partners," commented Dr Lawrence F Rozsnyai, director of Intellectual Property and Licensing. "We are continuing to secure and expand our proprietary position in the Aganocide compounds and related antimicrobial technologies."
NovaBay has recently filed additional patent applications including ones for compositions of matter of additional Aganocide compounds, methods of use and formulations, and is preparing further applications in other areas. Similar patent filings have been made in all major international countries that have significant pharmaceutical markets.
"The validation by the US Patent Office of the novelty of NVC-422 is yet one more important step in bringing this molecule to the market for the treatment and prevention of infectious diseases-a critical need as the excessive use of antibiotics is leading to a dramatic increase in the number of patients with antibiotic-resistant diseases," said Dr Ron Najafi, NovaBay's chairman and CEO. "We expect that the Aganocide compounds as the first non-antibiotic anti-infective will play a leading role as first line therapies in many indications, since they do not cause microbes to develop resistance."
According to the Centers for Disease Control and Prevention (CDC), "Antibiotic Resistance has been called one of the world's most pressing problems. Over the last decade, almost every type of bacteria has become stronger and less responsive to antibiotic treatment when it is really needed."
The Aganocide compounds are novel N-chlorinated antimicrobial molecules developed by NovaBay.
NovaBay Pharma is a biopharmaceutical company focused on developing innovative non-antibiotic, antimicrobial product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments.